Floatz logo

AMCASERTIB

Hepatocellular Carcinoma

Sumitomo Pharma Co., Ltd.Small moleculePhase 2Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
57/ 100
Competitive Position
65/ 100

Competitive context

521 Active assets in the Hepatocellular Carcinoma cohort.

Asset / SponsorPhaseRating
Huaier Granule
Tongji Hospital
Phase 4BBB
Adefovir
Bukwang Pharmaceutical
Phase 4BBB
Sorafenib
Bayer
Phase 4BBB
Carboplatin
AstraZeneca
Phase 4BB
Theprubicin
RWTH Aachen University
Phase 4BB

View all 50 →

Same molecule, other indications

AMCASERTIB is also rated in:

cholangiocarcinomaDormant
CCC
Indicative ·
54 / 100
View asset →
malignant urinary system neoplasmDormant
CCC
Indicative ·
53 / 100
View asset →
cancerDormant
CCC
Indicative ·
52 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →